You are leaving Amgevita.EU website and entering another Amgen website

You are now leaving Amgevita.EU
Amgen does not endorse or accept liability for sites controlled by third parties

Return to previous page Continue

Countries ▼

AE Reporting

This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. Please refer to the Summary of Product Characteristics for how to report adverse reactions.

AMGEVITA^® is authorised for the following indications by the European Commission:
AMGEVITA^® is an adalimumab biosimilar indicated for the treatment of rheumatoid arthritis, juvenile idiopathic arthritis, axial spondyloarthritis, psoriatic arthritis, psoriasis, paediatric plaque psoriasis, hidradenitis suppurativa, Crohn’s disease, paediatric Crohn’s disease, ulcerative colitis, uveitis and paediatric uveitis.

AMGEVITA^® (adalimumab) Summary of Product Characteristics. Available at: www.ema.europa.eu. Last revised March 2020.

▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.

The information contained in this website is for European healthcare professionals only

I understand and confirm I am an EU healthcare professional
Read more >

I am not an EU healthcare professional
Read more >

▼This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.